Table 4.
Multivariate cox analyses of biomarkers and clinical factors with OS
| High-grade serous carcinoma | Clear cell carcinoma | |||
|---|---|---|---|---|
| Factors | Hazard Ratio (95% CI) | HGSC P | Hazard Ratio (95% CI) | CCC P |
| Stage | ||||
| Early(I + II) | 1.000 | 1.000 | ||
| Late(III + IV) | 3.320(0.965–11.427) | 0.057 | 9.703(2.588–36.381) | 0.001 |
| Residual tumor | ||||
| < 1 cm | 1.000 | 1.000 | ||
| > 1 cm | 1.367(0.560–3.339) | 0.492 | 1.400(0.244–8.032) | 0.706 |
| Ascites | ||||
| No | 1.000 | 1.000 | ||
| Yes | 0.994(0.293–3.373) | 0.993 | 2.587(0.848–7.890) | 0.095 |
| Chemotherapeutic response | ||||
| Sensitive | 1.000 | 1.000 | ||
| Resistant | 3.803(2.170–6.664) | 0.000 | 3.562(1.063–11.936) | 0.040 |
| EGFR | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 1.244(0.653–2.370) | 0.507 | 0.044(0.003–0628) | 0.021 |
| HER2 | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 1.277(0.299–5.456) | 0.741 | 7.948(1.745–36.208) | 0.007 |
| PTEN | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 0.696(0.257–1.880) | 0.474 | 4.475(0.825–24.274) | 0.082 |
| AURKA | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 2.082(1.162–3.730) | 0.014 | 1.763(0.616–5.044) | 0.291 |
| BRCA1 | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 0.433(0.211–0.885) | 0.022 | 1.934(0.653–5.738) | 0.235 |
| BRCA2 | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 1.671(0.755–3.701) | 0.206 | 1.258(0.352–4.493) | 0.723 |
| PD-L1 | ||||
| Negative | 1.000 | 1.000 | ||
| Positive | 0.520(0.182–1.487) | 0.222 | 1.157(0.387–3.456) | 0.794 |
CI confidence interval
Bold value denotes P with statistical significance